Cite
HARVARD Citation
Erdos, J. et al. (2022). Mid- and long-term (at least 12 months) follow-up of patients with spinal muscular atrophy (SMA) treated with nusinersen, onasemnogene abeparvovec, risdiplam or combination therapies: A systematic review of real-world study data. European journal of paediatric neurology. pp. 1-10. [Online].